

Primerdesign™ Ltd

R00952

Influenza A, Influenza B and Human Respiratory Syncytial Virus

Kit version: 2

Influenza A (Flu A) - (M gene)

Influenza B (Flu B) - (NS1 and NEP genes)

Respiratory Syncytial Virus (RSV) - (M gene)

genesig® PLEX kit

100 tests

GENESIG

Kits by Primerdesign

Specificity of primers and probes last reviewed on:

30th May 2023

For general laboratory and research use only

Introduction

Influenza A

Influenza A virus (Flu A) is a member of the Orthomyxoviridae family and is responsible for causing Flu in humans and animals. Influenza is transmitted through the air in droplets containing the virus formed by coughs or sneezes. Symptoms in people include fever, sore throat, muscle pains, severe headache, coughing, weakness and fatigue. In more serious cases, influenza causes pneumonia, which can be fatal, particularly in young children and the elderly. Flu A causes annual epidemics due to genetic and antigenic variation caused by the high mutation rate in the segmented RNA genome that allows the virus to rapidly adapt to new hosts. Flu A can also infect and cause severe disease in birds, including domestic poultry. Occasionally the virus can be passed from infected poultry to humans.

Influenza B

Influenza B virus (Flu B) is a member of the Orthomyxoviridae family. Flu B is known to infect humans and seals, causing flu outbreaks. This limited host range is apparently responsible for the lack of Flu B caused influenza pandemics in contrast with those caused by the morphologically similar Flu A. Influenza is transmitted through the air in droplets containing the virus formed by coughs or sneezes. Symptoms in people include fever, sore throat, muscle pains, severe headache, coughing, weakness and fatigue. In more serious cases, influenza causes pneumonia, which can be fatal, particularly in young children and the elderly.

Respiratory Syncytial Virus

Human respiratory syncytial virus (RSV) is a negative sense, single-stranded RNA virus of the family Paramyxoviridae (subfamily: Pneumovirinae), which includes common respiratory viruses such as those causing measles and mumps.

RSV causes respiratory tract infections in patients of all ages. It is the major cause of lower respiratory tract infection during infancy and childhood. In temperate climates there is an annual epidemic during the winter months. In tropical climates, infection is most common during the rainy season. Natural infection with RSV does not induce protective immunity, and thus people can be infected multiple times.

For most people, RSV produces only mild symptoms, often indistinguishable from common colds and minor illnesses. RSV is also a common cause of pneumonia for young children. For some children, RSV can cause bronchiolitis, leading to severe respiratory illness requiring hospitalisation and, rarely, causing death. This is more likely to occur in patients that are immunocompromised, or infants born prematurely.

Specificity

The genesig®PLEX kit is designed for the in vitro detection of Influenza A, Influenza B and Human Respiratory Syncytial Virus. At the time of the most recent review, the assays within this kit are predicted to detect over 95% of sequences available from the GISAID EpiRSV database and over 95% of sequences from the GISAID EpiFlu database collected in the previous six years.

The dynamics of genetic variation means that new sequence information may become available after the initial design. Primerdesign™ periodically reviews the detection profiles of our kits and when required releases new versions.

The kit is predicted to cross-react with pangolin RSVA, which would produce a signal in the ROX channel for RSV.

If you require further information or have a specific question about the detection profile of this kit, then please send an email to techsupport@primerdesign.co.uk and our team will answer your question.

Kit contents

- **Multiplex primer/probe mix (100 reactions BROWN)**
FAM, VIC, ROX and Cy5 labelled (see table below)

Target	Fluorophore
Flu A	FAM
Flu B	Cy5
RSV	ROX
Internal control (IEC)	VIC

- **Multiplex positive control template (RED)**
- **Internal extraction control RNA (BLUE)**
- **2x Lyophilised OneStep Master Mix (GOLD)**
- **2x oasig™ resuspension buffer (BLUE)**
- **Template preparation buffer (YELLOW)**
for resuspension of positive control template
- **RNase/DNase free water (WHITE)**
for resuspension of primer/probe mix

Reagents and equipment to be supplied by the user

Real-time PCR Instrument

Extraction kit

This kit is recommended for use with genesig® EASY DNA/RNA Extraction kit. However, it is designed to work well with all processes that yield high quality RNA with minimal PCR inhibitors.

Pipettors and filter tips

Vortex and centrifuge

1.5 ml microtubes

qPCR plates or reaction tubes

Kit storage and stability

This kit is stable at room temperature but should be stored at -20°C on arrival. Once the lyophilised components have been resuspended, they should not be exposed to temperatures above -20°C for longer than 30 minutes at a time and unnecessary repeated freeze/thawing should be avoided. The kit is stable for six months from the date of resuspension under these circumstances.

Primerdesign™ does not recommend using the kit after the expiry date stated on the pack.

Suitable sample material

All kinds of sample material suited for PCR amplification can be used. Please ensure the samples are suitable in terms of purity, concentration, and RNA integrity. Always run at least one negative control with the samples. To prepare a negative control, replace the template RNA sample with RNase/DNase free water.

Dynamic range of test

Under optimal PCR conditions the kit can achieve priming efficiencies between 90-110% and detect less than 100 copies of target template.

Notices and disclaimers

This product is developed, designed and sold for research purposes only. It is not intended for human diagnostic or drug purposes or to be administered to humans unless clearly expressed for that purpose by the Food and Drug Administration in the USA or the appropriate regulatory authorities in the country of use. During the warranty period Primerdesign™ genesig® detection kits allow precise and reproducible data recovery combined with excellent sensitivity. For data obtained by violation to the general GLP guidelines and the manufacturer's recommendations the right to claim under guarantee is expired. PCR is a proprietary technology covered by several US and foreign patents. These patents are owned by Roche Molecular Systems Inc. and have been sub-licensed by PE Corporation in certain fields. Depending on your specific application you may need a license from Roche or PE to practice PCR. Additional information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Roche Molecular Systems, 1145 Atlantic Avenue, Alameda, CA 94501 or Applied Biosystems business group of the Applied Biosystems Corporation, 850 Lincoln Centre Drive, Foster City, CA 94404. In addition, the 5' nuclease assay and other homogeneous amplification methods used in connection with the PCR process may be covered by U.S. Patents 5,210,015 and 5,487,972, owned by Roche Molecular Systems, Inc. and by U.S. Patent 5,538,848, owned by The Perkin-Elmer Corporation.

Trademarks

Primerdesign™ is a trademark of Primerdesign Ltd.

genesig® is a registered trademark of Primerdesign Ltd.

oasig™ is a trademark of Primerdesign Ltd.

The PCR process is covered by US Patents 4,683,195, and 4,683,202 and foreign equivalents owned by Hoffmann-La Roche AG. BI, ABI PRISM® GeneAmp® and MicroAmp® are registered trademarks of the Applied Biosystems (Applied Biosystems Corporation). BIOMEK® is a registered trademark of Beckman Instruments, Inc.; iCycler™ is a registered trademark of Bio-Rad Laboratories, Rotor-Gene is a trademark of Corbett Research. LightCycler™ is a registered trademark of the Idaho Technology Inc. GeneAmp®, TaqMan® and AmpliTaqGold® are registered trademarks of Roche Molecular Systems, Inc., The purchase of the Primerdesign™ reagents cannot be construed as an authorization or implicit license to practice PCR under any patents held by Hoffmann-La Roche Inc.

Principles of the test

Real-time PCR

Individual primer and probes designed for each virus have been combined into a single reaction and these can be detected through the different fluorescent channels as described in the kit contents.

The primer and probe mix provided exploits the so-called TaqMan® principle. During PCR amplification, forward and reverse primers hybridize to the target RNA. Fluorogenic probes are included in the same reaction mixture which consists of a DNA probe labelled with a 5`-dye and a 3`-quencher. During PCR amplification, the probe is cleaved, and the reporter dye and quencher are separated. The resulting increase in fluorescence can be detected on a range of qPCR platforms.

Positive control

For a positive control, the kit contains a single positive control that contains templates for the three targets in the test. The kit positive control will give a Flu A signal through the FAM channel, a Flu B signal through the Cy5 channel and a RSV signal through the ROX channel. Each time the kit is used, at least one positive control reaction must be included in the run. A positive result indicates that the primers and probes for detecting each virus are working properly in that particular run. If a negative result is obtained the test results are invalid and must be repeated. Care should be taken to ensure that the positive control does not contaminate any other kit component which would lead to false positive results. This can be achieved by handling these components in a post PCR environment. Care should also be taken to avoid cross-contamination of other samples when adding the positive control to the run. This can be avoided by sealing all other samples and negative controls before pipetting the positive control into the positive control well.

Negative control

To validate any positive findings a negative control reaction should be included every time the kit is used. For this reaction the RNase/DNase free water should be used instead of template. A negative result indicates that the reagents have not become contaminated while setting up the run. It is also known as a No Template Control or NTC.

Internal RNA extraction control

When performing RNA extraction, it is often advantageous to have an exogenous source of RNA template that is spiked into the lysis buffer. This control RNA is then co-purified with the sample RNA and can be detected as a positive control for the extraction process. Successful co-purification and qPCR for the control RNA also indicates that PCR inhibitors are not present at a high concentration.

Within the multiplex primer/probe mix are primers and probes to detect the exogenous RNA using qPCR. The PCR primers are present at PCR limiting concentrations which allows multiplexing with the target sequence primers. Amplification of the control RNA does not interfere with detection of target RNA even when present at low copy number. The Internal control is detected through the VIC channel and gives a Cq value of 28+/-3 depending on the level of sample dilution.

Resuspension protocol

To minimise the risk of contamination with foreign RNA/DNA, we recommend that all pipetting be performed in a PCR clean environment. Ideally this would be a designated PCR lab or PCR cabinet. Filter tips are recommended for all pipetting steps.

1. Pulse-spin each tube in a centrifuge before opening.

This will ensure lyophilised primer and probe mix is in the base of the tube and is not lost upon opening the tube.

2. Resuspend the primer/probe mix in the RNase/DNase free water supplied, according to the table below:

To ensure complete resuspension, vortex the tube thoroughly.

Component – resuspend in water	Volume
Pre-PCR pack	
Multiplex primer/probe mix (BROWN)	110µl

3. Resuspend the internal control template and positive control template in the template preparation buffer supplied, according to the table below:

To ensure complete resuspension, vortex the tube thoroughly.

Component – resuspend in template preparation buffer	Volume
Pre-PCR heat-sealed foil	
Internal extraction control RNA (BLUE)	500µl
Post-PCR heat-sealed foil	
Positive control template (RED)*	500µl

*** This component contains high copy number template and is a VERY significant contamination risk. It must be opened and handled in a separate laboratory environment, away from the other components.**

4. Resuspend the lyophilised OneStep Master Mix in oasisig™ resuspension buffer, according to the table below:

Component – resuspend in oasisig™ resuspension buffer	Volume
Lyophilised OneStep Master Mix (GOLD)	525µl

RNA extraction

The internal extraction control RNA can be added to either lysis/extraction buffer or to the sample once it has been resuspended in lysis buffer.

DO NOT add the internal extraction control RNA directly to the unprocessed biological sample as this will lead to degradation and a loss in signal.

1. Add 4µl of the Internal extraction control RNA (**BLUE**) to each sample in RNA lysis/extraction buffer per sample.
2. Complete RNA extraction according to the manufacturer's recommended protocols.

OneStep RT-qPCR detection protocol

For optimum performance and sensitivity

All pipetting steps and experimental plate set up should be performed on ice. After the plate is prepared, proceed immediately to the OneStep amplification protocol. Prolonged incubation of reaction mixes at room temperature can lead to PCR artifacts that reduce the sensitivity of detection.

1. For each RNA sample prepare a reaction mix according to the table below:
Include sufficient reactions for positive and negative controls.

Component	Volume
Lyophilised OneStep Master Mix (GOLD)	10µl
Multiplex primer/probe mix (BROWN)	1µl
RNase/DNase free water (WHITE)	4µl
Final volume	15µl

2. Pipette 15µl of this mix into each well according to your qPCR experimental plate set up.
3. Pipette 5µl of RNA sample into each well according to your experimental plate set up.
For negative control wells use 5µl of RNase/DNase free water. The final volume in each well is 20µl.
4. Pipette 5µl of positive control template into each well according to your plate set up.
The positive control contains templates for Flu A, Flu B or RSV. The final volume in each well is 20µl.

OneStep RT-qPCR amplification protocol

Amplification conditions using lyophilised OneStep Master Mix

	Step	Time	Temp
	Reverse transcription	10 mins	55°C
	Enzyme activation	2 mins	95°C
Cycling x 50	Denaturation	10 secs	95°C
	DATA COLLECTION*	60 secs	60°C

* Fluorogenic data should be collected during this step through the FAM, VIC, ROX and Cy5 channels.

Interpretation of results

Positive control

The positive control well should give an amplification plot through the FAM channel (Flu A), the CY5 channel (Flu B) and the ROX channel (RSV). There is no internal control template within the positive control so the VIC channel should give no signal (flat amplification plot). The positive control signals indicate that the kit is working correctly to detect each virus.

No template control (NTC)

The NTC should give a flat line (flat amplification plots) through all channels. Signals in the NTC indicate cross contamination during plate set up.

Internal RNA extraction control

The Cq value obtained with the internal control will vary significantly depending on the extraction efficiency, the quality and quantity of RNA added to the PCR reaction and the individual machine settings. Cq values of 28 ± 3 are within the normal range. When amplifying a target sample with a high genome copy number, the internal extraction control may not produce an amplification plot. This does not invalidate the test and should be interpreted as a positive experimental result.

Sample data

Presence of the viruses are detected in the channels indicated in the kit contents section. Positive signals indicate positive tests for those viruses. It may be possible for samples to contain multiple viruses, therefore positive results in the FAM, Cy5 and ROX channels may be present.


Summary of data interpretation

Target (Cy5/FAM/ROX)	Internal extraction control (VIC)	Positive Control	Negative Control	Interpretation
FAM +	+ / -	+	-	Flu A POSITIVE RESULT
Cy5 +	+ / -	+	-	Flu B POSITIVE RESULT
ROX +	+ / -	+	-	RSV POSITIVE RESULT
-	+	+	-	NEGATIVE RESULT


+ / -	+ / -	+	≤35	EXPERIMENT FAILED Due to test contamination
+ / -	+ / -	+	>35	*
-	-	+	-	SAMPLE PREPARATION FAILED
+ / -	+ / -	-	+ / -	EXPERIMENT FAILED

Positive control template (**RED**) is expected to amplify between Cq 16 and 23. Failure to satisfy this quality control criterion is a strong indication that the experiment has been compromised.

* Where the test sample is positive, and the negative control is positive with a Cq >35, the sample must be reinterpreted based on the relative signal strength of the two results:



If the sample amplifies > 5 Cq earlier than the negative control, then the sample should be reinterpreted (via the table above) with the negative control verified as negative.



If the sample amplifies < 5 Cq earlier than the negative control, then the positive sample result is invalidated, and the result should be determined inconclusive due to test contamination. The test for this sample should be repeated.